23andMe (NASDAQ:ME) Stock Price Down 0.3% - Time to Sell?

23andMe Holding Co. (NASDAQ:ME - Get Free Report)'s stock price was down 0.3% during trading on Monday . The stock traded as low as $3.64 and last traded at $3.78. Approximately 157,237 shares changed hands during trading, a decline of 26% from the average daily volume of 213,546 shares. The stock had previously closed at $3.79.

23andMe Price Performance

The company has a market capitalization of $103.43 million, a price-to-earnings ratio of -0.16 and a beta of 1.14. The company's 50-day moving average price is $3.68 and its two-hundred day moving average price is $5.92.

23andMe (NASDAQ:ME - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter. The business had revenue of $44.07 million during the quarter, compared to the consensus estimate of $50.30 million. 23andMe had a negative return on equity of 129.98% and a negative net margin of 318.39%.

Institutional Trading of 23andMe

Hedge funds have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC boosted its holdings in 23andMe by 410.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company's stock worth $35,000 after acquiring an additional 71,204 shares during the last quarter. Point72 DIFC Ltd bought a new position in 23andMe in the 2nd quarter valued at $43,000. Levin Capital Strategies L.P. purchased a new stake in shares of 23andMe during the 2nd quarter valued at $61,000. AQR Capital Management LLC boosted its holdings in shares of 23andMe by 145.8% in the 2nd quarter. AQR Capital Management LLC now owns 444,222 shares of the company's stock worth $174,000 after buying an additional 263,468 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of 23andMe during the 2nd quarter valued at approximately $203,000. Institutional investors and hedge funds own 36.10% of the company's stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.